Cargando…

TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells

To develop a chitosan-based nonviral gene carrier capable of delivering genes specifically into hepatoma cells, a bifunctional peptide composed of the TAT (transactivator of transcription) peptide and luteinizing hormone-releasing hormone (LHRH) was conjugated with low molecular weight chitosan, res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lanxia, Dong, Xia, Zhu, Dunwan, Song, Liping, Zhang, Hailing, Leng, Xigang G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061174/ https://www.ncbi.nlm.nih.gov/pubmed/24959076 http://dx.doi.org/10.2147/IJN.S61392

Ejemplares similares

Transactivator of transcription (TAT) peptide– chitosan functionalized multiwalled carbon nanotubes as a potential drug delivery vehicle for cancer therapy
por: Dong, Xia, et al.
Publicado: (2015)

Simultaneous monitoring of the drug release and antitumor effect of a novel drug delivery system-MWCNTs/DOX/TC
por: Dong, Xia, et al.
Publicado: (2017)

Local gene delivery via endovascular stents coated with dodecylated chitosan–plasmid DNA nanoparticles
por: Zhu, Dunwan, et al.
Publicado: (2010)

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer
por: Obayemi, J. D., et al.
Publicado: (2020)

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers
por: Roy, Jyoti, et al.
Publicado: (2019)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
por: Visapää, Harri
Publicado: (2017)

LHRH agonists and the prevention of breast and ovarian cancer.
por: Pike, M. C., et al.
Publicado: (1989)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
por: McClelland, H. R., et al.
Publicado: (1992)

(99m)Tc-LHRH in tumor receptor imaging
por: Hao, Dawei, et al.
Publicado: (2017)

Antitumor Activity and Mechanism of Action of Hormonotoxin, an LHRH Analog Conjugated to Dermaseptin-B2, a Multifunctional Antimicrobial Peptide
por: Couty, Mickael, et al.
Publicado: (2021)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
por: Curtis, Kelly K., et al.
Publicado: (2014)

Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide
por: Taheri, Azade, et al.
Publicado: (2011)

Chitosan-Based Membranes as Gentamicin Carriers for Biomedical Applications—Influence of Chitosan Molecular Weight
por: Supernak, Milena, et al.
Publicado: (2023)

LHRH analogues in breast cancer: clever, but do we need them?
por: Smith, I. E.
Publicado: (1991)

Low Molecular Weight Hydroxyethyl Chitosan-Prednisolone Conjugate for Renal Targeting Therapy: Synthesis, Characterization and In Vivo Studies
por: He, Xia-kai, et al.
Publicado: (2012)

Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies
por: Fernandes, Julio C, et al.
Publicado: (2012)

SUN-063 Usefulness of a LHRH Test with Low Dose of Triptorelin Pamoate in the Diagnosis of Precocious Puberty in Girls
por: Llano, Juan Pablo, et al.
Publicado: (2020)

Conjugates of Chitosan with β-Cyclodextrins as Promising Carriers for the Delivery of Levofloxacin: Spectral and Microbiological Studies
por: Le-Deygen, Irina M., et al.
Publicado: (2023)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

Subclinical leprosy manifesting as a reversal reaction after LHRH agonist administration
por: Carmo, R.L.M.L., et al.
Publicado: (2018)

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)
por: Emons, Günter, et al.
Publicado: (2014)

A brain glioma gene delivery strategy by angiopep-2 and TAT-modified magnetic lipid-polymer hybrid nanoparticles
por: Qiao, Lanxin, et al.
Publicado: (2020)

Depicting Binding-Mediated Translocation of HIV-1 Tat Peptides in Living Cells with Nanoscale Pens of Tat-Conjugated Quantum Dots
por: Lin, Chien Y., et al.
Publicado: (2017)

From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.
por: Corbin, A.
Publicado: (1982)

Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer.
por: Rutqvist, L. E., et al.
Publicado: (1992)

Antitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cells
por: Li, Xiaoyong, et al.
Publicado: (2016)

Conjugation to the Cell-Penetrating Peptide TAT Potentiates the Photodynamic Effect of Carboxytetramethylrhodamine
por: Srinivasan, Divyamani, et al.
Publicado: (2011)

Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA
por: Malhotra, Meenakshi, et al.
Publicado: (2013)

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer
por: Ndinguri, Margaret, et al.
Publicado: (2023)

Enhanced Cellular Entry and Efficacy of Tat Conjugates by Rational Design of the Auxiliary Segment
por: Zhang, Pengcheng, et al.
Publicado: (2014)

Examining the Cellular Transport Pathway of Fusogenic Quantum Dots Conjugated With Tat Peptide
por: Dai, Jie, et al.
Publicado: (2022)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2017)

Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles
por: Malhotra, Meenakshi, et al.
Publicado: (2013)

Optimizing molecular weight of octyl chitosan as drug carrier for improving tumor therapeutic efficacy
por: Zhang, Min, et al.
Publicado: (2017)

Gold nanoparticles with chitosan, N-acylated chitosan, and chitosan oligosaccharide as DNA carriers
por: Abrica-González, Paulina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_orl344qo7gkpfpjb18enpn28c0